(Bloomberg) -- Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less-than-expected benefit in a late-stage trial. After 24 weeks ...
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Sanofi shares slid Thursday after the company reported underwhelming ...
Hosted on MSN
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More
Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD). The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback